Healio Minute Podcast, Hematology Oncology Edition: Top Headlines - Week of November 21, 2022
Click Here to Manage Email Alerts
In this edition, lung cancer screening critically low across the U.S, first in-human CRISPR test with gene replacement, racial and economic segregation linked to higher cancer mortality rates, and more.
Read the full coverage here:
Lung cancer screening rates in US ‘simply unacceptable’
First CRISPR-based cell therapy to use gene replacement feasible, safe for solid tumors
Racial, economic segregation linked to cancer mortality
Onivyde regimen extends OS in metastatic pancreatic ductal adenocarcinoma
Immunotherapy a ‘significant improvement’ for treatment of multiple myeloma
References:
Davies FE, et al. New therapeutic agents for relapsed/refractory multiple myeloma: CAR T and bispecific antibodies. Presented at: 40th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; Nov. 9-11, 2022.
Foy SP, et al. Abstract 1478. Presented at: Society for Immunotherapy of Cancer Annual Meeting; Nov. 8-12, 2022; Boston.
Zhang L, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5382.
Collapse
Click Here to Manage Email Alerts
